ReviewCureus2026
Simvastatin as a Biological Adjunct to Guided Bone Regeneration and Related Implant Regenerative Procedures: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tooth extraction is followed by progressive alveolar ridge resorption, which can compromise implant positioning, peri-implant hard tissue support, and esthetic outcomes. Guided bone regeneration (GBR) and related implant-site regenerative approaches are therefore frequently used to improve peri-implant healing. Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, has shown osteopromotive, anti-inflammatory, and angiogenic effects and has recently been explored as a local adjunct in implant-associated regenerative procedures. This systematic review evaluated the available human and animal evidence on localized simvastatin used with GBR or related regenerative protocols during implant placement. This systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and registered in PROSPERO (CRD420251037455). Electronic searches of PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane CENTRAL, Google Scholar, and ClinicalTrials.gov were performed from database inception to April 30, 2025. Randomized controlled trials (RCTs), controlled clinical studies, and animal studies evaluating local simvastatin in implant-associated regenerative procedures were eligible. Data were synthesized qualitatively because of heterogeneity in study design, simvastatin delivery systems, comparator protocols, and outcome measures. Five studies were included: three human clinical studies and two animal studies. In the human studies, simvastatin was associated with reduced peri-implant bone loss (0.975±0.0438 mm versus 1.356±0.0384 mm; P<0.0001), improved probing depth and bleeding scores, greater bone width gain (5.55±0.80 mm versus 3.36±0.19 mm), and higher bone mineral density (640.02±262.22 versus 297.38±82.94) compared with controls. In the animal studies, simvastatin improved bone-to-implant contact and bone area; for example, grafted bone-to-implant contact at four weeks increased from 59.5% in controls to 84.3% in simvastatin-treated sites, while grafted bone area increased from 51.4% to 75.9%. Implant stability findings were mixed, and no major adverse effects were reported. The available evidence suggests that locally delivered simvastatin may improve hard tissue regeneration and selected peri-implant clinical outcomes when used with GBR or related implant regenerative protocols. However, the evidence base is limited by the small number of studies, mixed human and animal designs, and heterogeneity in simvastatin concentration, carrier systems, and follow-up periods. Larger, well-designed clinical trials with standardized protocols are needed before routine clinical use can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.